Skip to main content
OpenTrials
Completed

NCT Number: NCT01610687

A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis

An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Muscle Hypertonia Muscle Spasticity Muscular Diseases Musculoskeletal Diseases Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Spasticity

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Rivermead Rehabilitation Centre

Oxford, OX3 7LD, United Kingdom

About this study

Patients who participated in the placebo controlled phase of this study and opted to continue receiving open label GW-1000-02 entered the follow-on extension of the study and completed symptom assessments to determine whether they were continuing to receive clinical benefit from GW-1000-02.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged at least 18 years.
  • Multiple Sclerosis of any type.
  • Stable Multiple Sclerosis symptomatology during the four weeks before study entry.
  • Symptoms of the required severity (>50 mm on a 100 mm Visual Analogue Scale severity scale) in least one of the specified impairment categories; spasticity, muscle spasms, disturbed bladder control, neuropathic pain, limb tremor.
  • A stable medication regime during the four weeks before study entry.
  • Willing to abstain from cannabis or cannabinoids for at least seven days before study entry, and during the study.
  • Agreed either to use effective contraception during the study and for three months thereafter, or had been surgically sterilised or, if female, were post-menopausal.
  • Clinically acceptable laboratory results for pre-study screening.
  • Willing and able to undertake and comply with all study requirements.
  • Willing and able to read, consider and understand the subject information and consent form and give written informed consent. Subjects unable to read or to sign the document procedures were treated as detailed in the Declaration of Helsinki.
  • Willing for their general practitioner, and consultant if appropriate, to be informed of study participation.
  • Willing for their name to be notified to Home Office for participation in the study.

Exclusion criteria

  • Known or strongly suspected to be abusing drugs, including alcohol.
  • Not prepared to abstain from cannabis or cannabinoids during the study.
  • Current or past addiction to cannabis.
  • Known or suspected to have had an adverse reaction to cannabinoids causing psychosis or other severe psychiatric illness.
  • History of any type of schizophrenia, any other psychotic illness, or other significant psychiatric illness or personality disorder other than depression associated with chronic illness.
  • Received any drug containing levodopa (Sinemet®, Sinemet plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®).
  • Serious cardiovascular disorder including angina, uncontrolled hypertension, or an uncontrolled symptomatic cardiac arrhythmia.
  • Significant renal or hepatic impairment as shown in medical history or indicated by laboratory results.
  • History of epilepsy.
  • Terminal illness or other condition in which placebo medication would be inappropriate.
  • Pregnant, lactating or at risk of pregnancy.
  • Participated in any other clinical research study during the 12 weeks before study entry.
  • Planned hospital admission between study entry and Visit 6.
  • Planned travel outside the UK between study entry and Visit 6.

Treatment and study plan

GW-1000-02

Drug

Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.

Other names: Sativex

Primary outcomes

  1. Incidence of Adverse Events as a Measure of Patient Safety

    Time frame: up to1206 days

    The number of patients who experienced an adverse event during the course of this extension study is presented

Secondary outcomes

  1. Mean Number of Sprays of Study Medication Taken During the Last 6 Days of Treatment

    Time frame: up to 1206 days

    A categorical summary was produced of the mean number of sprays per day during the last six days of treatment, and the mean number of sprays was rounded to the nearest whole number for categorisation.

  2. Change From Baseline in Mean Intoxication 100 mm Visual Analogue Scale Scores at Week 18.

    Time frame: 18 weeks

    Intoxication levels were recorded on a Visual Analogue Scale, where 0 equals 'no intoxication' and 10 equals 'extreme intoxication'. A decrease in score indicates an improvement in intoxication levels.

  3. Investigator Assessed Global Severity Score at Week 18

    Time frame: week 18

    The investigator rated the global severity of the subject's primary condition since entry into the study using a five-point verbal rating scale-5: 1=much worse, 2=worse, 3=no change, 4=better, 5=much better. The number of patients which were considered better or much better (scores 4 and 5) at week 18 of the study better is presented.

  4. Change From Baseline in the Mean Pain 100 mm Visual Analogue Scale Score at Week 18

    Time frame: week 18

    A clinical assessment of pain was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no pain and 100 = worst possible pain. A decrease in score indicates an improvement.

  5. Change From Baseline in the Mean Spasticity 100 mm Visual Analogue Scale Score at Week 18

    Time frame: week 18

    A clinical assessment of spasticity was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no spasticity and 100 = worst possible spasticity. A decrease in score indicates an improvement.

  6. Change From Baseline in the Mean Tremor 100 mm Visual Analogue Scale Score at Week 18

    Time frame: week 18

    A clinical assessment of tremor was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no tremor and 100 = worst possible tremor. A decrease in score indicates an improvement.

  7. Change From Baseline in the Mean Bladder Problems 100 mm Visual Analogue Scale Score at Week 18

    Time frame: 18 weeks

    A clinical assessment of bladder problems was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no bladder problems and 100 = worst possible bladder problems. A decrease in score indicates an improvement.

Sponsors and collaborators

Lead sponsor

Jazz Pharmaceuticals

Industry

Registry information

Official study title

A Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension

Important dates

Study start
2001
Primary completion
2005
Study completion
2005
First posted
Jun 4, 2012
Registry last updated
Jan 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.